Publication date: Nov 16, 2024
We studied the current state and factors associated with the acceptance or hesitancy of booster doses of the coronavirus disease 2019 (COVID-19) vaccine among patients with autoimmune and rheumatic diseases (ARDs) in Japan. A single-center cross-sectional survey was conducted among outpatients with ARDs who visited the Immuno-Rheumatology Center at St. Luke’s International Hospital from 1 October to 30 November in 2023. We investigated patient characteristics, COVID-19 vaccination-related status, decision-making preferences, health-related status and independent factors associated with the acceptance or hesitancy of booster doses of the COVID-19 vaccine. A total of 241 patients were included in the analyses, and 198 patients (82. 2%) received booster doses while 43 (17. 8%) did not. Older age (adjusted odds ratio [aOR] = 0. 43, 95% CI: 0. 19, 0. 95, P = 0. 037), having rheumatoid arthritis (RA) (aOR = 0. 41, 95% CI: 0. 19, 0. 92, P = 0. 030) and having a physician recommend receiving the vaccine (aOR = 0. 47, 95% CI: 0. 23, 0. 95, P = 0. 035) were independently associated with receiving booster doses. The main reasons for hesitancy regarding booster doses were concerns about adverse reactions and long-term safety. Our findings could help physicians counsel patients with ARDs regarding their acceptance of COVID-19 vaccine booster doses to promote appropriate decision-making.
Concepts | Keywords |
---|---|
Coronavirus | Autoimmune Diseases |
Covid | COVID-19 |
Japan | Japan |
October | Rheumatic Diseases |
Outpatients | Vaccination Hesitancy |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | rheumatic diseases |
disease | MESH | coronavirus disease 2019 |
disease | MESH | rheumatoid arthritis |
pathway | KEGG | Rheumatoid arthritis |
disease | MESH | Autoimmune Diseases |